Cyroport, a cryogenic logistics company, and Morphotek, a subsidiary of Eiasi Inc, report that Cryoport is providing end-to-end cold chain logistics support for shipments of Morphotek's research and development materials.

Cryoport is currently supporting 52 clinical trials for advanced therapies and regenerative medicines, including 10 in Phase III, for biopharmaceutical companies globally.

In December 2015, the company opened its US headquarters in Irvine, California. Cryoport has international operations centers located in Rotterdam, the Netherlands and Singapore.

The Irvine facility is designed to service large-scale manufacturing and logistics operations in support of the company’s expected growth. In total, the facility has 27,600 square feet of space, which is more than double that of the company’s previous location. The additional space will aid in the implementation of processes automating workflow, the enhancement of quality processes, and the scaling of the company’s operations to accommodate increasing client demand.

Source: Cryport